雷尼替丁联合多潘立酮治疗小儿消化不良的临床效果

Analysis of Clinical Efficacy of Ranitidine Combined with Domperidone in the Treatment of Dyspepsia in Children

目的:观察小儿消化不良患者采用不同药物治疗的临床效果及安全性。方法:随机将2015年4月-2017年4月收治的140例小儿消化不良患者分为观察组(予以雷尼替丁与多潘立酮联合治疗,n=70)和对照组(予以雷尼替丁独用治疗,n=70),对两组小儿消化不良患者采用不同药物治疗后的临床症状消除时间、临床治疗效果及药物不良反应发生情况进行比较。结果:患者接受治疗后的临床治疗效果分别为观察组94.29%,对照组82.86%,差异有统计学意义(P<0.05);观察组和对照组的药物不良反应发生率分别为5.71%和17.14%,差异有统计学意义(P<0.05);组间腹痛、腹胀、食欲不振及嗳酸等症状临床症状消除时间比较,观察组所用时间分别为(1.26±0.52)、(2.05±1.35)、(3.32±1.26)、(2.36±1.63)d,明显短于对照组的(2.53±0.73)、(2.84±1.26)、(4.51±1.46)、(3.47±1.24)d,差异有统计学意义(P<0.05)。结论:雷尼替丁与多潘立酮联合治疗在小儿消化不良患者临床治疗中的应用效果显著,有效减轻了疾病症状,提高了药物治疗的安全性和有效性,对促进患者康复具有促进作用,值得推广。

Objective： To observe the clinical efficacy and safety of different drugs in children with dyspepsia.Method ： A total of 140 children with dyspepsia admitted to our hospital from April 2015 to April 2017 were randomly divided into the observation group（Ranitidine combined with Domperidone treatment, n=70） and the control group（Ranitidine the only treatment, n=70）, two groups of children with dyspepsia in patients with different drug treatment after the elimination of clinical symptoms, clinical efficacy and adverse drug reactions were compared.Result： The clinical effects of the two groups after treatment were 94.29% in the observation group and 82.86% in the control group, respectively, the difference was significant（P〈0.05）.The adverse drug reaction rates in the observation group and the control group were 5.71% and 17.14%, respectively, the difterence was significant（P〈0.05）, the disappear time of stomachache, ventosity, inappetence, oxyrygmia were （1.26 ± 0.52）d, （2.05 ± 1.35）d, （3.32 ± 1.26）d and （2.36 ± 1.63）d, respectively in the observation group, the control group were （2.53 ± 0.73）d, （2.84 ± 1.26）d, （4.51 ± 1.46）d, （3.47 ±1.24）d, the differences were significant（P〈0.05）.Conclusion： The combination therapy of Ranitidine and Domperidone has significant efIect in clinical treatment of children with dyspepsia, effectively alleviating the symptoms of the disease, improving the safety and effectiveness of drug treatment and promoting the rehabilitation of patients, and is worth promoting.